SCHEDULE OF STOCK WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares |
12 Months Ended | |
|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
| Number of warrants, outstanding and exercisable, beginning balance | 1,455,119 | 214,883 |
| Weighted average exercise price, outstanding and exercisable, beginning balance | $ 6.10 | $ 4.49 |
| Number of warrants, warrants issued | 1,240,236 | |
| Weighted average exercise price, warrants issued | $ 6.38 | |
| Number of warrants, outstanding and exercisable, ending balance | 1,455,119 | 1,455,119 |
| Weighted average exercise price, outstanding and exercisable, ending balance | $ 6.10 | $ 6.10 |
| Weighted average remaining contract term warrants outstanding and exercisable | 3 years 2 months 1 day | 4 years 2 months 1 day |
| X | ||||||||||
- Definition Weighted Average Exercise Price Per Warrant outstanding and exercisable, balance. No definition available.
|
| X | ||||||||||
- Definition Weighted Average Exercise Price Per Warrant, issued. No definition available.
|
| X | ||||||||||
- Definition Remaining Contract Term (years) Warrants outstanding and exercisable. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|